About GBS
GBS is a venture capital firm founded in 1996. It is primarily based out of Melbourne, Australia. As of Aug 2024, GBS has invested in 35 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Food and Agriculture Tech. Most recently it participated in the $***** Series D round of Moximed Overall, GBS portfolio has seen 9 IPOs and 10 acquisitions including key companies like Cirrus Logic, Celladon and Neurovance. A lot of funds co-invest with GBS, with names like Novartis sharing a substantial percentage of its portfolio. GBS has team of 2 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 4 more
Portfolio IPOs
Portfolio Soonicorns
GBS's List of Top Investments
GBS has a portfolio of 35 companies. Their most notable investments are in Nuon Therapeutics and Celladon.Their portfolio spans across United States, Australia and United Kingdom. They have invested in Life Sciences, HealthTech, Food and Agriculture Tech and 10 other sectors, across stages such as Series A, Series B and 4 more. Here is the list of top investments by GBS:1. Cirrus Logic
Internet first brand offering analog, mixed-signal, and audio DSP integrated circuits. It developed Cirrus Logic’s Noise Reduction and Echo Cancellation (NREC) technology to identify what audio inputs are important and what needs to be heard on the receiver’s end for enabling clear communication of speakers' voice.
Key facts about Cirrus Logic
- Founded Year: 1984
- Location: Austin (United States)
- Stage: Public
- Employee Count: 1,907 as on Aug 31, 2026
- Investors: GBS, Crosslink Capital and 4 Others
- Highlight: Public
2. Celladon
Telecommunications solutions provider empowering connectivity through innovation and future-ready technology. The company delivers impactful and reliable telecommunications solutions. Specializing in telegraphy, satellite communications, and telephony, it pioneers trends in the telecommunications sector, offering services from mobile connectivity to secure transactions. It provides cutting-edge solutions, including next-generation mobile networks, AI, and IoT, ensuring accessibility and reliability. VoIP solutions redefine traditional telephony, offering cost-effective, scalable, and cloud-based communication for businesses. The company harnesses IoT data for efficiency, innovation, and smarter decision-making. Blockchain technology enhances the safety of every digital interaction. It delivers fixed VoIP telephony and designs reliable connectivity, tailoring each project to meet specific needs. The company is committed to digital success, navigating the future of telecommunications with confidence.
Key facts about Celladon
- Founded Year: 2000
- Location: San Diego (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2023
- Stage: Public
- Total Funding till date: $117M
- Employee Count: 56 as on Dec 31, 2022
- Investors: Lundbeck Foundation, Enterprise Partners Venture Capital and 13 Others
- Latest Funding Round: Post IPO, Nov 18, 2015, $*****
- Highlight: Public
3. Hydrexia
Provider of hydrogen production, storage, transportation, and application technology solutions. The company offers comprehensive solutions across the hydrogen energy industry chain. It provides gas separation and purification technology. The company also offers magnesium-based solid-state hydrogen storage and transportation technologies.
Key facts about Hydrexia
- Founded Year: 2006
- Location: Brisbane (Australia)
- Stage: Series D
- Total Funding till date: $17.1M
- Employee Count: 32 as on Aug 31, 2026
- Investors: Southern Cross Venture Partners, GBS and 6 Others
- Latest Funding Round: Series D, Sep 28, 2023, $*****
- Highlight: Editors' Pick
4. Neurovance
Neurovance is a clinical stage neuroscience-focused company. Following the development of centanafadine (formerly EB-1020) for adult Attention Deficit Hyperactivity Disorder (ADHD), the company is developing EB-1020 SR for adolescent & pediatric ADHD. Centanafadine (CTN) is a novel triple reuptake inhibitor that modulates norepinephrine, dopamine and, to a lesser extent, serotonin reuptake in a ratio of 1:6:14, respectively to improve focus, attention and executive function.
Key facts about Neurovance
- Founded Year: 2011
- Location: Cambridge (United States)
- Stage: Acquired
- Total Funding till date: $53M
- Employee Count: 7 as on Dec 31, 2016
- Investors: Tekla Capital Management, GBS and 3 Others
- Latest Funding Round: Series B, Jan 04, 2017, $*****
- Highlight: Acquired
5. Hatchtech
Hatchtech, a specialty pharmaceutical company developing Xeglyze Lotion (previously DeOvoLotion ), a proprietary next generation head lice treatment. Xeglyze is a topical lotion containing an inhibitor of metalloproteinases known to impede a number of physiological processes involved in all stages of the louse lifecycle from egg to adult. Xeglyze Lotion recently completed two phase III clinical studies conducted under a Special Protocol Agreement with the U.S. Food and Drug Administration (FDA).
Key facts about Hatchtech
GBS's Investments by Stage
GBS has made 9 investments in Series A stage with an average round size of $10.4M, 5 investments in Series B stage with an average round size of $13.3M and 3 investments in Post IPO stage with an average round size of $6.22M.Stage of entry | No. of Investments |
|---|---|
Series A | 9 |
Series B | 5 |
Post IPO | 3 |
Seed | 3 |
Series C | 3 |
Others | 1 |
Note: We have considered here, only first round of investments
GBS's Investments by Sector
GBS has a diverse portfolio, with companies operating in the Life Sciences, Sustainability Tech, High Tech, Consumer and Enterprise Applications. Notably, it has invested in 33 Tech companies, 22 Enterprise (B2B) companies, 7 Consumer (B2C) companies and at least 7 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 20 |
Sustainability Tech | 5 |
High Tech | 3 |
Consumer | 2 |
Enterprise Applications | 2 |
Others | 6 |
Note: We have considered here, only first round of investments
GBS's Investments by Geography
GBS has made most investments in United States (14), followed by Australia where it has made 8 investments.Country | No. of Investments |
|---|---|
United States | 14 |
Australia | 8 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
GBS's recent investments
GBS has not made any investment in 2026 so far.Here are the most recent investments by GBS:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Aug 07, 2024 | United States | Series D | 7471 | [+8] | |
Aug 16, 2022 | United States | Series C | 3977 | [+5] | |
Jan 27, 2019 | Australia | Series C | 1104 | - | |
Mar 30, 2017 | United States | Series C | 8778 | [+5] | |
Jan 07, 2016 | Australia | Series B | 6243 | [+4] |
IPOs and Publicly Listed companies in GBS's Portfolio
9 of GBS's portfolio companies have become public. Pacific Knowledge Systems got listed on the Australian Securities Exchange (ASX), in Jun 2019 at marketcap of $15.9M and Celladon got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $214M.Here are GBS's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 07, 2019 | - | - | 6902 | |
Jan 30, 2014 | Feb 06, 2012 | Series D | 4941 | |
Jan 31, 2013 | Mar 17, 2005 | Series B | 6522 | |
Nov 13, 2008 | Apr 21, 2010 | Post IPO | 5011 | |
Jul 20, 2006 | Apr 21, 2010 | Post IPO | 7774 |
Acquired companies in GBS's Portfolio
10 companies from GBS's portfolio have been acquired. The most recent acquisition was Foodbomb in Sep 2023 by Ordermentum for $*****.Here are GBS's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 20, 2023 | - | - | 1996 | |
Nov 08, 2021 | Jan 13, 2014 | Series B | 5832 | |
Feb 07, 2018 | Aug 2008 | Series A | 5321 | |
Sep 08, 2017 | May 08, 2006 | Series A | 1062 | |
Mar 02, 2017 | May 30, 2012 | Seed | 1678 |
Team profile of GBS
GBS has a team of 2 members located in Australia. GBS's team does not sit on the board of any company as of now.Co-investors of GBS
Over the past 21 years, 123 investors have co-invested in GBS's portfolio companies. This includes funds and angels.
- Invested before GBS: Delphi Ventures, Johnson & Johnson Innovation – JJDC and 22 others have invested in rounds before GBS. There are 2 companies where Delphi Ventures has invested before GBS and 1 company where Johnson & Johnson Innovation – JJDC has invested before GBS.
- Top Co-investors of GBS: 37 investors entered a company along with GBS. These include investors like Novartis (2 companies).
- Invested after GBS: A total of 62 investors have invested in GBS's portfolio after their investments. Top Investors include RA Capital Management (2 companies), Vivo Capital (2 companies) and Square 1 Bank (2 companies).
Recent News related to GBS
•
Moximed Closes $61 Million Series Dsvdaily.com•Aug 20, 2024•Moximed, Elevage Medical Technologies, Patient Square Capital, Cormorant Capital and 7 others
•
Moximed secures $91m to advance MISHA knee systemMedicalDeviceNetwork•Aug 14, 2024•Moximed, Elevage Medical Technologies, Warren Point Capital, New Enterprise Associates and 8 others
•
Moximed Completes Closing of Series D FinancingOrthoworld•Aug 13, 2024•Moximed, Elevage Medical Technologies, Cormorant Capital, Warren Point Capital and 12 others
•
Moximed Raises $40M for Knee OA DeviceOrthopedics•Sep 02, 2022•Moximed, Runway Growth Capital, Advent Life Sciences, New Enterprise Associates and 5 others
•
Moximed raises $40M for implantable shock absorberMassDevice•Aug 16, 2022•GBS, New Enterprise Associates, Runway Growth Capital, Morgenthaler and 4 others
•
Moximed Closes Oversubscribed $50MM Financing RoundVCA Online•Mar 16, 2017•Moximed, Advent Life Sciences, Future Fund, New Enterprise Associates and 4 others
•
Finanznachrichten - Börse & Wirtschaft aktuellwallstreet:online•Apr 23, 2016•Spinifex Pharmaceuticals, Canaan, GBS, Brandon Capital Partners and 2 others
•
Elastagen snags A$13 mln Series B - PE HubPE Hub•Jan 07, 2016•Elastagen, Korea Investment Partners, Wellcome, Brandon Capital Partners and 3 others
•
Vertex Ventures participates in Moximed $33m Series B round - DealStreetAsiaDeal Street Asia•May 08, 2015•Moximed, GBS, New Enterprise Associates, Gilde Healthcare and 2 others
•
Moximed springs to $33m Series B round - MassDeviceMassDevice•May 07, 2015•Moximed, GBS, New Enterprise Associates, Gilde Healthcare and 2 others
